| 11.35 0.3 (2.71%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.34 | 1-year : | 30.21 |
| Resists | First : | 19.98 | Second : | 25.87 |
| Pivot price | 11.77  |
|||
| Supports | First : | 10.47 | Second : | 8.71 |
| MAs | MA(5) : | 11.29 |
MA(20) : | 12.09 |
| MA(100) : | 20.9 |
MA(250) : | 0 | |
| MACD | MACD : | -1.9 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 21.7 |
D(3) : | 22.6 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 33.2 | Low : | 10.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVMN ] has closed above bottom band by 31.2%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.38 - 11.43 | 11.43 - 11.49 |
| Low: | 10.68 - 10.74 | 10.74 - 10.8 |
| Close: | 11.26 - 11.35 | 11.35 - 11.44 |
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Thu, 30 Jul 2026
Stempoint Capital LP Buys 125,581 Shares of Evommune, Inc. $EVMN - MarketBeat
Thu, 30 Jul 2026
EVMN|Evommune Inc|Price:11.100|Chg%:-0.150 - TradingKey
Tue, 28 Jul 2026
Evommune Inc (EVMN) Institutional Confidence - TradingKey
Mon, 27 Jul 2026
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Fri, 24 Jul 2026
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - Financial Health Score - po-news-eg.net
Fri, 10 Jul 2026
Evommune (EVMN) CFO boosts stake with 1,000-share buy, repays $10,160 profit - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 114.7 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 4,270 (K) |
| EPS | -2.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.46 |
| Profit Margin | 0 % |
| Operating Margin | -900 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -45 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -2.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -5.38 |
| PEG Ratio | 0 |
| Price to Book value | 1.34 |
| Price to Sales | 40.88 |
| Price to Cash Flow | -5.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|